Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 18.35 USD 7.06% Market Closed
Market Cap: 616.6m USD
Have any thoughts about
Grail Inc?
Write Note

Grail Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Grail Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Cost of Revenue
-$54.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-5%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$12.9B
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.5B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-25%
No Stocks Found

Grail Inc
Glance View

Market Cap
609.3m USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
22.17 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Grail Inc's Cost of Revenue?
Cost of Revenue
-54.8m USD

Based on the financial report for Dec 31, 2023, Grail Inc's Cost of Revenue amounts to -54.8m USD.

What is Grail Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-44%

Over the last year, the Cost of Revenue growth was -44%.

Back to Top